D781DC00001_GOG-3098_DESTINY-Endometrial01: An Open-Label, Randomized, Controlled, Multicenter, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus SoC in Patients with HER2-Expressing (IHC3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Objective

Clinical Trial Details

Clinical Trial Categories

  • Cancer
  • Gynecologic Cancer
Contact
Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org

Location

  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000